How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

2017736 citationsJournal Article

Authors

Silvio E. Inzucchi · Yale University

Bernard Zinman · Mount Sinai Hospital

David Fitchett · St. Michael's Hospital

Christoph Wanner

Ele Ferrannini · Istituto di Fisiologia Clinica

Martin Schumacher · University of Freiburg

Claudia Schmoor · University of Freiburg

Abstract

In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 41, Issue 2, pp. 356-363

DOI: 10.2337/dc17-1096

Field-Weighted Citation Impact: 51.79